

Laurie Little  
Senior Vice President, Investor Relations

Valeant Pharmaceuticals International, Inc.  
400 Somerset Corporate Blvd., Bridgewater, NJ 08807  
Tel: 949-461-6002  
Email: [ir@valeant.com](mailto:ir@valeant.com)  
[www.valeant.com](http://www.valeant.com)

September 3, 2015

**BY EMAIL AND U.S. MAIL**

The Honorable Elijah E. Cummings  
Ranking Member  
Committee on Oversight and  
Government Reform  
United States House of Representatives  
2471 Rayburn House Office Building  
Washington, DC 20515

The Honorable Bernard Sanders  
Ranking Member  
Subcommittee on Primary Health and  
Retirement Security  
Committee on Health, Education,  
Labor, and Pensions  
United States Senate  
440 Hart Senate Office Building  
Washington, DC 20510

RE: Valeant Pharmaceuticals International, Inc.

Dear Ranking Member Cummings and Ranking Member Sanders:

On behalf of Valeant Pharmaceuticals International, Inc. ("Valeant"), I write in response to your letter of August 14, 2015 regarding certain drug prices. Although the specific documents and information referenced in your letter are highly proprietary and confidential, Valeant is pleased to provide the following information in response to your inquiry.

Valeant is a global specialty pharmaceuticals and medical devices company headquartered in Laval, Quebec with nearly 19,500 employees worldwide, approximately 5,700 of whom Valeant employs in the United States. Valeant's growth has been facilitated in large part by its investments in the United States, and the company has continued to expand its U.S.-based operations, reinvest in its U.S. business, and create good, quality jobs here in the United States. Valeant has 12 manufacturing sites throughout the United States, with its largest facilities in Rochester, New York; Greenville, South Carolina; Saint Louis, Missouri; Tampa, Florida; and Clearwater, Florida. And Valeant is in the process of expanding its U.S. manufacturing facilities – working with local officials, businesses, and stakeholders to expand its presence and increase its investment in the communities where Valeant operates. The company takes great efforts to ensure that it has the most talented, committed, hard-working, and ethical workforce in the industry, and it is extremely proud of what it has accomplished.

Valeant puts patients and customers first by maintaining the highest ethical standards in the industry. Valeant is proud of the work it does to promote innovative medicines, which are preventing costly complications of chronic diseases, reducing the number of visits to the emergency room and the length of hospital stays, and helping patients avoid major surgeries.

The prices set by pharmaceutical companies – including Valeant – reflect the value of these products in the acute care setting, as well as hospital reimbursement rates. With regard specifically to Isuprel and Nitropress, these are two drugs selected out of a portfolio of hundreds of medications. These are drugs that are only used by hospitals – they are not sold in pharmacies – in accordance with specific surgical procedures. This means that whenever the protocol calls for use of these drugs, they are used. Patients are never denied these drugs when the protocols call for their use.

The analysis for pricing for a drug is quite complex. Before Valeant acquired the rights to these two drugs, as part of a portfolio of drugs that it acquired from Marathon Pharmaceuticals earlier this year, the prior owner was evaluating the benefits of these drugs to the system – to both patients and hospitals – and had concluded that the drugs were significantly underpriced. Following the acquisition, Valeant completed the analysis that had been commenced by Marathon, and ultimately decided to adjust the prices to better reflect the benefits that they provide.

When it comes to prescriptions that patients fill at the pharmacy, Valeant maintains patient assistance programs for medicines. The company provides a number of these patient assistance programs to remove the financial obstacles that may keep patients from obtaining the medications they need. Valeant is deeply committed to improving patient care, including offering help to those patients who need it.

Valeant hopes that this information is helpful to your investigation. Please do not hesitate to contact me with any questions.

Sincerely,



Laurie Little

Senior Vice President, Investor Relations

cc: The Honorable Jason Chaffetz  
Chairman, House Committee on Oversight and Government Reform